#Antibody Drug Conjugates Market Size

[marketreports-blog]

According to Nova one advisor, the global antibody drug conjugates market size was USD 11.65 billion in 2023, calculated at USD 12.75 billion in 2024, and is expected to reach around USD 28.61 billion by 2033, expanding at a CAGR of 9.4% from 2024 to 2033. North America dominated the market with the largest revenue share of 52.95% in 2023.

[alicetleibowitz]

Discover the latest advancements and market trends in the Antibody Drug Conjugates (ADCs) Market. Explore the growth drivers, key players, and innovative technologies shaping the future of ADCs in oncology and beyond.

[juanvmartinez2024]

Precision in Oncology: Antibody Drug Conjugates Market pioneers targeted cancer therapies, combining monoclonal antibodies with cytotoxic agents to deliver potent treatments directly to cancer cells, advancing personalized medicine.

[ramkumarss]

Antibody Drug Conjugates Market Size, Share | Growth drivers 2023

According to Precision Business Insights, the global Antibody Drug Conjugates Market is poised to grow at a significant CAGR of 12.6% during forecast period 2023-29

The global antibody drug conjugates market size was valued at USD 6.84 billion in 2022 and is poised to grow at a significant CAGR of 12.6% during the forecast period 2023-29. It also includes market size and projection estimations for each of the five major regions from 2023 to 2029. The research report includes historical data, trending features, and market growth estimates for the future. Furthermore, the study includes a global and regional estimation and further split by nations and categories within each region. The research also includes factors and barriers to the antibody drug conjugates market growth, as well as their impact on the market's future growth. The report gives a comprehensive overview of both primary and secondary data.  

View the detailed report description here - https://www.precisionbusinessinsights.com/market-reports/antibody-drug-conjugates-market              

The global antibody drug conjugates market segmentation: 1) By Drugs : Kadcyla, Adcertis

2) By Mechanism Of Action : CD30 Antibodies, HER2 Antibodies

3) By Application : Breast Cancer, Lymphoma

The primary factors of the antibody drug conjugates market drivers are the increasing incidences of cancer. The antibody drug conjugates market report helps to provide the best results for business enhancement and business growth. It further helps to obtain the reactions of consumers to a novel product or service. It becomes possible for business players to take action for changing perceptions. It uncovers and identifies potential issues of the customers. It becomes easy to obtain the reactions of the customers to a novel product or service. It also enlightens further advancement, so it suits its intended market.

The antibody drug conjugates market researchreport gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America was the largest region in the antibody drug conjugates market report, accounting for the highest share in 2022. It was followed by Asia Pacific, and then the other regions. Request sample report at - https://www.precisionbusinessinsights.com/request-sample/?product_id=23717                The important profiles and strategies adopted by antibody drug conjugates market key players Roche Holding AG (Switzerland) Pfizer Inc. (U.S.) Bayer HealthCare (Germany) Progenics Pharmaceuticals (U.S.) Roche Holding AG (Switzerland) ImmunoGen, Inc. (U.S.) Celldex Therapeutics (U.S.) AbbVie Inc. (U.S.) Millennium Pharmaceuticals (U.S.) Agensys, Inc. (U.S.), covered here to help them in strengthening their place in the market.

About Precision Business Insights: We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:

Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: sales@precisionbusinessinsights.com Kemp House, 152 – 160 City Road, London EC1V 2NX Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

[neha24blog]

Antibody Drug Conjugates Market Outlook On The Basis Of Application, Technology, Region And Forecast To 2030  : Grand View Research Inc.

San Francisco, 24 Feb 2023: The Report Antibody Drug Conjugates Market Size, Share & Trends Analysis Report Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable, Non-cleavable), By Payload Technology, And Segment Forecasts, 2022 – 2030 The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR…

[blog-site-for-market-research]

Forecasting the Antibody Drug Conjugate Market: Trends and Outlook

Market Overview –

The antibody drug conjugate (ADC) market is a segment within the pharmaceutical industry that focuses on a class of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, offering a promising approach to cancer treatment. This market is driven by the increasing incidence of cancer worldwide, the need for more effective and targeted therapies, and advancements in biotechnology and drug delivery systems.

One of the key drivers of the ADC market is the demand for novel cancer treatments with improved efficacy and fewer side effects compared to traditional chemotherapy. ADCs offer a targeted approach, delivering cytotoxic drugs directly to cancer cells while sparing healthy tissues, thereby reducing systemic toxicity and enhancing patient outcomes.

Furthermore, the growing understanding of tumor biology and the identification of specific molecular targets have facilitated the development of ADCs tailored to different types of cancer. This personalized approach to treatment holds promise for patients with refractory or relapsed cancers who may not respond to conventional therapies.

The antibody drug conjugate market is experiencing rapid expansion, propelled by advancements in anti-drug conjugates. These innovative therapies combine the targeting precision of antibodies with potent anti-cancer drugs, offering promising treatment options for various cancers. With ongoing research and development efforts, the market for anti drug conjugates is poised for continued growth in the fight against cancer.

The COVID-19 pandemic has highlighted the importance of innovative therapies like ADCs in addressing unmet medical needs, especially in oncology. While the pandemic initially disrupted clinical trials and supply chains, the resilient nature of the biopharmaceutical industry has enabled continued research and development in this field.

However, challenges such as the complexity of ADC manufacturing, high development costs, and regulatory hurdles pose barriers to market growth. Nonetheless, with ongoing research and collaborations among pharmaceutical companies, academic institutions, and regulatory agencies, the ADC market is expected to witness significant expansion in the coming years, offering new hope to cancer patients worldwide.

With a predicted compound annual growth rate (CAGR) of 16.70% from 2022 to 2030, the antibody drug conjugate market, which was valued at USD 1.98 billion in 2021, is expected to rise from USD 2.31 billion in 2022 to USD 6.81 billion by 2030.

Segmentation –

As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.

Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.

Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.

Based on product, it is segmented into Kadcyla, Adcertis and others.

Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.

Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer, and others.

Regional Analysis –

The antibody drug conjugate (ADC) market's regional dynamics depend on factors like research infrastructure, regulatory environment, and healthcare access. North America dominates, driven by robust research and development activities and favorable regulatory pathways. Europe follows, with a strong presence of biopharmaceutical companies and supportive policies for innovative therapies. Asia-Pacific is emerging as a significant market, fueled by investments in biotechnology and a growing patient population. Other regions, such as Latin America and Africa, are gradually gaining traction as awareness of ADC therapies increases. Market players must navigate regional differences in reimbursement policies and healthcare systems while capitalizing on opportunities for collaboration and expansion.

Key Players –

Antibody drug conjugate companies include ADC Therapeutics, Takeda Pharmaceutical Company Ltd., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Daiichi Sankyo Company Ltd., Pfizer Inc., Seagen Inc., Gilead Sciences Inc., Astellas Pharma, among others.

Related Reports –

Steam Autoclave

Diagnostic Imaging

Neonatal Thermoregulation

Immunotherapy Drugs

For more information visit at MarketResearchFuture

[stevenwilliam12]

The Evolving B7-H3 Market: Size, Forecast, and Competitive Dynamics by 2034

Introduction to B7-H3 and Its Role in Oncology

B7-H3, a member of the B7 family of immune checkpoint molecules, has emerged as a promising target in cancer immunotherapy due to its significant role in immune evasion and tumor progression. Overexpressed in various cancers such as prostate cancer, non-small cell lung cancer (NSCLC), breast cancer, and pediatric tumors like neuroblastoma, B7-H3 has sparked interest for therapeutic interventions. As research into immune checkpoint inhibitors continues, the B7-H3 antibody market and B7-H3 inhibitors market size are poised for significant growth. These therapies are expected to provide new hope for patients, particularly those with cancers that exhibit resistance to conventional treatments.

B7-H3 Inhibitors Market Overview

The B7-H3 inhibitors market is emerging as a key segment within the broader immuno-oncology landscape. B7-H3-targeted therapies, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cell therapies, are being actively developed to treat cancers with high B7-H3 expression. The B7-H3 inhibitors market size is expected to experience substantial growth over the next decade as clinical trials progress and regulatory approvals become imminent. The market’s growth is also fueled by the increasing prevalence of cancers where B7-H3 is overexpressed, combined with a growing focus on personalized therapies that target tumor-specific biomarkers.

Target Population for B7-H3 Inhibitors

The target population for B7-H3 inhibitors consists primarily of patients diagnosed with cancers that exhibit high B7-H3 expression. Key cancer types that are likely to benefit from B7-H3 inhibitors include:

Prostate Cancer: B7-H3 is frequently overexpressed in prostate cancer, particularly in advanced stages, making it an ideal therapeutic target for mAbs and other B7-H3-targeted therapies.

Non-Small Cell Lung Cancer (NSCLC): B7-H3 has been identified as a key player in the progression of NSCLC, with high levels of expression in a significant portion of patients, making it a promising target for immunotherapy.

Breast Cancer: Certain subtypes of breast cancer, such as triple-negative breast cancer (TNBC), show elevated levels of B7-H3, and targeting this molecule may provide significant therapeutic benefits.

Pediatric Cancers: Neuroblastoma, a common pediatric cancer, is known for its overexpression of B7-H3, making it a prime target for B7-H3-directed therapies. Other pediatric cancers, such as medulloblastoma, may also benefit from these therapies.

The growing understanding of B7-H3's role in tumor progression is likely to expand the target population for these therapies, making them applicable to a broader range of cancers over time.

Competitive Landscape of the B7-H3 Inhibitors Market

The B7-H3 inhibitors market is highly competitive, with several biopharmaceutical companies actively developing innovative therapies targeting B7-H3. These therapies include monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T therapies, all of which are progressing through clinical trials. Some of the key players in the B7-H3 antibody market and inhibitors landscape include:

MacroGenics: MacroGenics is at the forefront of developing enoblituzumab, a monoclonal antibody targeting B7-H3. The company is conducting clinical trials to assess the efficacy of enoblituzumab in various cancers, including prostate cancer and NSCLC.

AstraZeneca: Known for its work in antibody-drug conjugates (ADCs), AstraZeneca is advancing B7-H3-targeted ADCs to deliver potent cytotoxic drugs directly to cancer cells, offering a more precise treatment option for patients with B7-H3-positive tumors.

ImmunoGen: ImmunoGen is developing B7-H3-targeted ADCs designed to deliver toxic payloads specifically to cancer cells expressing B7-H3. Their approach aims to improve treatment outcomes while minimizing off-target effects.

Novartis: Novartis is pursuing CAR-T cell therapies that target B7-H3, particularly in pediatric cancers like neuroblastoma, which is known for its high B7-H3 expression.

Other Emerging Players: Other companies such as GSK, Bristol Myers Squibb, and AbbVie are also exploring B7-H3 inhibitors and therapies, positioning themselves as key competitors in this growing market.

As the clinical trials for these therapies progress and more results become available, the competitive landscape will continue to evolve, with collaborations and partnerships likely to play a significant role in the development of B7-H3-targeted treatments.

B7-H3 Market Forecast to 2034

The B7-H3 market is projected to experience rapid growth through 2034, driven by advances in drug development, a deeper understanding of tumor biology, and increasing investment in oncology research. The B7-H3 inhibitors market size is expected to reach multi-billion-dollar valuations by the early 2030s, as several promising B7-H3-targeted therapies are expected to gain regulatory approval in key markets like the U.S., Europe, and Asia-Pacific.

Several factors are driving this growth:

Rising Cancer Incidence: The global rise in cancer incidence, particularly in prostate, lung, and breast cancers, is expected to increase demand for targeted therapies like B7-H3 inhibitors.

Improved Patient Stratification: Biomarker-based approaches are improving the ability to identify patients most likely to benefit from B7-H3-targeted therapies, driving adoption of these treatments.

Combination Therapies: B7-H3 inhibitors are being evaluated in combination with other immunotherapies, such as PD-1/PD-L1 inhibitors, to enhance treatment efficacy and overcome resistance mechanisms in tumors.

Regulatory Approvals: The approval of B7-H3 inhibitors by regulatory agencies such as the U.S. FDA and European Medicines Agency (EMA) will accelerate market growth, especially as clinical trial results continue to support their safety and efficacy.

Conclusion

The B7-H3 inhibitors market is positioned for significant expansion, with promising therapies on the horizon for a variety of cancers. As the understanding of B7-H3’s role in immune evasion and tumor progression deepens, the market will see an increasing number of targeted therapies moving through clinical trials and toward regulatory approval. With a growing target population, robust competition, and increasing investment in cancer immunotherapy, the B7-H3 market size is expected to experience substantial growth, reaching new heights by 2034. The future of B7-H3-targeted therapies holds great promise for improving cancer care and outcomes for patients worldwide.

Latest Reports

Contraceptive Devices Market | Crohns Disease Cd Market | Cutaneous T-cell Lymphoma Market | Diabetic Neuropathy Market | Ehlers-danlos Syndrome Market | Encephalitis Market | Epidermolysis Bullosa Market | Familial Amyloid Polyneuropathy Market | Healthcare Competitive Benchmarking | Hepatic Encephalopathy Epidemiology Forecast | Hepatitis B Virus Market | Hepatitis D Market | Hereditary Spastic Paraplegias Market | Hpv-induced Cancers Market | Human Papillomavirus Positive Cancer Market | Hyperkalemia Market | Nontuberculous Mycobacteria Infection Market | Post-bariatric Hypoglycemia Market | Postsurgical Pain Market | Primary Progressive Multiple Sclerosis Ppms Market | Surgical Stapling Devices Market | Vascular Access Devices Market | Vascular Dementia Market | Wound Closure Devices Market | Xerostomia Market

[jayanthitbrc]

Global Immunotoxin Market Analysis 2024: Size Forecast and Growth Prospects

The immunotoxin global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Immunotoxin Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The immunotoxin market size has grown strongly in recent years. It will grow from $55.94 billion in 2023 to $60.97 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the discovery of target antigens, advancements in monoclonal antibody technology, preclinical efficacy studies, clinical trials and regulatory approval, and identification of resistance mechanisms.

The immunotoxin market size is expected to see strong growth in the next few years. It will grow to $86.29 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to the increasing incidence of cancer, rising demand for natural and organic products, expansion of the cosmetic industry, expansion of R and D financing, and improving healthcare infrastructure. Major trends in the forecast period include precision medicine approach, enhanced targeting strategies, multifunctional immunotoxins, combination therapies, and advancements in monoclonal antibody technology.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Scope Of Immunotoxin MarketThe Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Immunotoxin Market Overview

Market Drivers -The increasing incidence of breast cancer is expected to propel the growth of the immunotoxin market going forward. Breast cancer refers to a type of cancer that forms in the cells of the breast. The rising incidence of breast cancer is primarily due to improved screening, lifestyle changes, and increased life expectancy. Immunotoxins help in breast cancer by targeting and killing cancer cells while sparing healthy cells, reducing side effects associated with traditional chemotherapy. For instance, in 2023 according to the American Cancer Society, a US-based non-profit organization, there were 300,590 new cases of breast cancer reported, showing an increase compared to the 290,560 cases reported in 2022. Therefore, an increasing incidence of breast cancer is driving the growth of the immunotoxin market.

Market Trends - Major companies operating in the immunotoxin market are focused on developing antibody-drug conjugates (ADCs) to enhance the specificity and efficacy of cancer treatment. ADCs are biopharmaceutical medicines that are intended to be used as targeted cancer treatments. Antibody-drug conjugates are made up of an antibody coupled to a cytotoxic medication, enabling targeted drug delivery to cancer cells that express a specific antigen. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, received full U.S. Food and Drug Administration (FDA) approval for TIVDAK, a first antibody-drug conjugate designed to treat patients with metastatic or recurrent cervical cancer. The toxic payload of TIVDAK is monomethyl auristatin E, a microtubule-disrupting chemical that causes cell death. This novel mechanism leads to its efficiency in cancer treatment. TIVDAK showed statistically significant increases in overall survival, making it a promising alternative for individuals with recurrent or metastatic cervical cancer.

The immunotoxin market covered in this report is segmented –

1) By Type: Anthrax Based Toxins, Diphtheria Toxin (DT) And Derivatives, Pseudomonas Exotoxin (PE) And Derivatives, Ribosome Inactivating Proteins Based Immunotoxins, Ribonucleases-Based Immunotoxins, Other Types 2) By Application: Solid Tumors, Leukemias, Other Applications 3) By End User: Hospitals And Clinics, Cancer And Radiation Therapy Centers, Research Labs, Other End-Users

Get an inside scoop of the immunotoxin market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15828&type=smp

Regional Insights - North America was the largest region in the immunotoxin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunotoxin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies - Major companies operating in the immunotoxin market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Seagen Inc., Orion Corporation, GenScript, Cytek Biosciences, MacroGenics Inc., Sutro Biopharma Inc., Sorrento Therapeutics Inc., Innate Pharma Inc., Cayman Chemical, ImmunoGen Inc., Mersana Therapeutics, Molecular Templates Inc., Celldex Therapeutics, CytImmune Sciences Inc., Enzo Life Sciences Inc.

Table of Contents 1. Executive Summary 2. Immunotoxin Market Report Structure 3. Immunotoxin Market Trends And Strategies 4. Immunotoxin Market – Macro Economic Scenario 5. Immunotoxin Market Size And Growth ….. 27. Immunotoxin Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[alicetleibowitz]

Unlocking targeted therapies, the Antibody Drug Conjugates Market pioneers precision medicine in oncology. Advancements offer new hope and improved outcomes for patients battling cancer worldwide.

[ramkumarss]

Antibody Drug Conjugates Market size was valued at USD 6.84 billion in 2022 and is expected to reach USD 11.87 billion by 2029, at a CAGR of 12.6% during the forecast period 2023-2029. ADCs are a type of biopharmaceutical used to treat cancer that consists of an antibody that selectively targets a tumour antigen and a cytotoxic agent linked together by a chemical linker. ADCs are designed to allow the cytotoxic substance to be targeted specifically to kill cancer cells while having a minimal effect on healthy tissue. Antibody drug conjugates are made up of three parts: an antibody specific for the target associated antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody.

[insightfulblogz]

Protein A Resin Market Applications and Future Prospects Details for Business Development, 2032

Protein A resin is a crucial component in the biopharmaceutical industry, specifically used for the purification of monoclonal antibodies (mAbs), which are widely employed in treating cancers, autoimmune diseases, and infectious diseases. By binding selectively to the Fc region of antibodies, Protein A resin facilitates efficient and scalable antibody purification during chromatography. This resin has become indispensable in manufacturing therapeutic antibodies, ensuring high purity and yielding superior performance. As the demand for biologics continues to grow, the use of Protein A resin in downstream processing is expected to expand.

The Protein A Resin Market Size was valued at USD 1.34 billion in 2023, and is expected to reach USD 3.08 billion by 2032, and grow at a CAGR of 9.7% over the forecast period 2024-2032.

Future Scope

The future of Protein A resin lies in improving its durability, reusability, and cost-effectiveness. Innovations in the formulation are being developed to enhance its binding capacity and operational lifespan, making it suitable for large-scale biomanufacturing processes. Additionally, ongoing research aims to improve the resin’s ability to work with emerging antibody formats, including bispecifics and antibody-drug conjugates. As biologic therapies and biosimilars continue to proliferate, Protein A resin technologies will evolve to meet the increased demand for efficient and scalable antibody purification processes.

Trends

Recent trends in Protein A resin focus on enhancing efficiency and reducing production costs in the biopharmaceutical industry. New generations of the resin are being engineered with higher binding capacities, allowing for greater throughput in antibody purification. Furthermore, the market is seeing a rise in sustainable resins that can withstand multiple cycles without compromising on quality, reducing waste and operational costs. The push for single-use technologies in the bioprocessing industry is also influencing the Protein A resin market, with disposable resin formats becoming increasingly popular for specific applications.

Applications

Protein A resin is predominantly used in the purification of monoclonal antibodies through affinity chromatography. It plays a vital role in downstream bioprocessing, where it ensures the selective isolation of antibodies from complex biological mixtures. The resin is also used in the purification of other Fc-containing fusion proteins and biosimilars, expanding its application across a range of therapeutic products. Moreover, Protein A resin has applications in academic research and clinical development, where high-purity antibodies are required for diagnostic and experimental purposes.

Key Points

Essential in the purification of monoclonal antibodies used in treating cancer and autoimmune diseases.

Supports large-scale biomanufacturing with selective binding to the Fc region of antibodies.

Ongoing advancements aim to improve reusability, binding capacity, and compatibility with new antibody formats.

Plays a critical role in the purification of biosimilars and fusion proteins in the biopharmaceutical industry.

The demand for sustainable and single-use resins is influencing current market trends.

Conclusion

As the biopharmaceutical industry continues to innovate, Protein A resin remains at the forefront of monoclonal antibody purification technologies. With advancements focused on increasing efficiency, reducing costs, and improving sustainability, the resin is expected to play an even larger role in the future of bioprocessing. The ability to evolve alongside emerging biologic therapies and formats ensures that Protein A resin will remain a key component in the production of life-saving therapies.

Read More Details: https://www.snsinsider.com/reports/protein-a-resin-market-3364 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[globalindustrytrends]

Mammalian Cell Culture Dominates Biologics CDMO Industry

The global biologics contract development and manufacturing organization market achieved revenue of USD 17.1 billion in 2024 and is expected to grow at a rate of 11.0% between 2024 and 2030, reaching USD 31.8 billion by the end of the forecast period. This expansion is largely driven by the increasing prevalence of chronic diseases, the growing trend of outsourcing R&D activities, collaborations between biologics CDMOs and businesses for new product launches, and the rising aging population.

In 2023, the drug substance segment led the market, generating USD 8,525.4 million. Factors such as the rise in biologics approvals, particularly from the FDA, robust clinical pipelines, and lower failure rates of biologic drugs are boosting the demand for drug substances. Additionally, the biologics industry’s growth is propelling the demand for processes, often outsourced to CDMOs by small and mid-sized pharmaceutical firms. Outsourced biologics development activities include assay development, toxicology studies, and the establishment of master cell banks.

The expanding biopharma sector is driving strong demand for biologics outsourcing services. Small and mid-sized biotech companies are increasingly relying on outsourcing due to limited capacities and R&D capabilities.

Meanwhile, large pharmaceutical companies are also outsourcing R&D activities to biologics CDMOs, which offer comprehensive solutions aimed at reducing R&D costs, mitigating risks, and allowing companies to focus on core competencies for greater efficiency. This trend suggests that the biologics outsourcing market will experience significant growth in the coming years.

In 2023, mammalian cell culture was the leading segment, accounting for around 56% of the market share. This dominance is attributed to the growing development of more complex biologics, such as antibody-drug conjugates and multi-specific antibodies.

Moreover, the increasing demand for biologics CDMOs from pharmaceutical companies is boosting growth in this segment. Major players like Samsung Biologics, Lonza, and WuXi Biologics are expected to expand their mammalian cell culture capacities by 30–40% over the next decade.

By 2030, the biologics CDMO market in North America is projected to reach USD 7,802.9 million in revenue. This growth is driven by factors such as the increasing aging population, the rising incidence of chronic and serious diseases, and growing R&D investments by pharmaceutical and biotech companies. For instance, the U.S. elderly population, aged 65 and above, increased from 50 million in 2018 to 55 million in 2021.

According to the CDC, chronic illnesses such as diabetes, cancer, and heart disease were the leading causes of death in the U.S., costing healthcare systems over USD 4 trillion in 2021. Furthermore, data from the Partnership to Fight Chronic Disease (PFCD) suggests that approximately 45% of the U.S. population has at least one chronic disease, with 165 million Americans expected to have multiple chronic conditions by 2025.